HOBOKEN, NJ, April 8 /CNW/ - Anavex Life Sciences Corp. ("Anavex") (OTCBB: AVXL)
today announced the appointment of Dr. Christopher Shackleton as an
advisor to the Company.
Dr. Shackleton is a prominent, uniquely qualified physician and surgeon,
clinical investigator, information technologist, and corporate
finance/healthcare solutions consultant. He holds triple specialist
credentials in medical and surgical disciplines, and has a track record
of success as a laboratory and clinical researcher/investigator. In
addition, Dr. Shackleton has a strong publication record and is a
renowned innovator, pioneer and leader in the development and
deployment of new clinical techniques and treatment modalities. In
addition to obtaining his medical education and training from the
University of British Columbia, University of Toronto and Harvard
Medical School, Dr. Shackleton studied corporate finance, financial
markets and financial derivatives at The London School of Economics and
Political Science and rose to the rank of full professor at the
University of California at Los Angeles (UCLA) School of Medicine. He
is also on the Board of Trustees of the Fraser Institute.
"We are extremely fortunate to have Dr. Shackleton join our team. As a
very experienced physician, we believe he will be a strong asset to
Anavex. His medical credentials and financial acumen make him well
qualified to provide us with strategic advice on numerous important
business initiatives," said Dr. Cameron Durrant, Executive Chairman of
"I look forward to speaking with various stakeholders about Anavex and
ANAVEX 2-73, the company's lead compound for Alzheimer's disease.
Preclinical results have been very encouraging and it is exciting to
see 2-73 entering clinical trials," said Dr. Christopher Shackleton.
"Alzheimer's disease has evolved into one of the most challenging and
costly health-care issues we face. Its impact on individuals and their
loved ones is devastating while the societal and economic costs are
staggering and rapidly increasing. There is a compelling need for
interventions that go beyond the limited symptomatic treatment afforded
by currently available drugs. The disappointing yield achieved thus far
by anti-amyloid targeted strategies has led to renewed interest in
molecules with novel mechanisms of action, such as the Anavex platform
About Alzheimer's Disease
While Alzheimer's disease is most common in people over the age of 65,
it can strike adults of any age irrespective of their gender,
background or socioeconomic status. According to the Alzheimer's
Association, an estimated 5.4 million Americans are currently living
with Alzheimer's disease. The number of Americans aged 65 and over with
Alzheimer's is estimated to reach 7.7 million in 2030. This represents
a 50 percent increase from the 5.2 million Americans aged 65 and older
who are currently affected. The Alzheimer's Association further
projects that the number of Americans aged 65 and older who are
affected by Alzheimer's disease may triple to between 11 and 16 million
by 2050 unless there are developments to prevent or more effectively
treat the disease.
About ANAVEX 2-73
ANAVEX 2-73 is the first of a new class of oral, disease-modifying drugs
being studied to potentially treat Alzheimer's disease itself, versus
treating its symptoms.
About Anavex Life Sciences Corp.
Anavex Life Sciences Corp. (www.anavex.com) is a specialty pharmaceutical company engaged in the discovery and
development of novel drug candidates for the treatment of neurological
diseases and cancer. The Anavex proprietary SIGMACEPTOR™ Discovery
Platform involves the rational design of drug compounds targeted to
specific receptors involved in the modulation of multiple cellular
biochemical signaling pathways.
The SIGMACEPTOR™-N program involves the development of novel drug
candidates that target neurological and neurodegenerative diseases
(Alzheimer's disease, epilepsy, depression, pain). The company's lead
drug candidates exhibit high affinity for sigma receptors, which have
been extensively documented as potentially valuable drug targets and
have demonstrated anti-amnesic and neuroprotective properties. A
portfolio of back-up compounds to ANAVEX 2-73 are also in development.
Anavex is a publicly traded company under the symbol AVXL.
Statements in this press release that are not strictly historical in
nature are forward-looking statements. These statements are only
predictions based on current information and expectations and involve a
number of risks and uncertainties. Forward-looking statements in this
press release include that our lead drug candidate has potentially
valuable anti-amnesic and neuroprotective properties, and that ANAVEX
2-73 is the first of a new class of oral, disease-modifying drugs which
could potentially treat Alzheimer's disease. Actual events or results
may differ materially from those projected in any of such statements
due to various factors, including the risks and uncertainties inherent
in drug discovery and development, which include, without limitation,
the potential failure of development candidates to advance through
preclinical studies or demonstrate safety and efficacy in clinical
testing and the ability to pass clinical trials so as to move on to the
next phase, our ability to retain key employees and our ability to
finance development or satisfy the rigorous regulatory requirements for
new drugs. Competitors may develop better or cheaper alternatives to
our products. Readers are cautioned not to place undue reliance on
these forward-looking statements, which speak only as of the date
hereof. All forward-looking statements are qualified in their entirety
by this cautionary statement and Anavex Life Sciences Corp. undertakes
no obligation to revise or update this press release to reflect events
or circumstances after the date hereof.
SOURCE Anavex Life Sciences Corp.
For further information:
Anavex Life Sciences Corp.
Research & Business Development
Shareholder & Media Relations
Outside North America: +1 (416) 489-0092